Miocarditis

  1. Díaz Fernández, B. 1
  2. García Campos, A. 1
  3. Pérez Domínguez, M. 1
  4. González Juanetey, J.R. 1
  1. 1 Servicio de Cardiología. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. La Coruña. España. CIBERCV
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades cardiovasculares (VIII)

Serie: 13

Número: 42

Páxinas: 2423-2432

Tipo: Artigo

DOI: 10.1016/J.MED.2021.09.019 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Myocarditis is an inflammatory disease of the myocardium that is widely heterogeneous, both in regard to its form of clinical presentation and its etiology, histopathology, and long-term prognosis. Nowadays, both its diagnosis and especially its treatment are a challenge that requires an integrated approach which includes everything from routine techniques, such as an echocardiogram and the titration of drugs for heart failure, to highly complex procedures, such as an endomyocardial biopsy and mechanical circulatory support.

Referencias bibliográficas

  • Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno Blanes J, Felix SB. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48.
  • Sawalha K, Abozenah M, Kadado AJ, Battisha A, Al-Akchar M, Salerno C. Systematic review of COVID-19 related myocarditis: Insights on management and outcome. Cardiovasc Revasc Med. 2021;23:107-13.
  • Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104(9):1076-82.
  • Leone O, Pieroni M, Rapezzi C, Olivotto I. The spectrum of myocarditis: from pathology to the clinics. Virchows Arch. 2019;475(3):279-301.
  • Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74.
  • Nakagawa M, Sato A, Okagawa H, Kondo M, Okuno M, Takamatsu T. Detection and evaluation of asymptomatic myocarditis in schoolchildren: Report of four cases. Chest. 1999;116(2):340-5.
  • Felker G, Weimin H, Hare J, RH H, Baughman K, Kasper E. The spectrum of dilated cardiomyopathy. Medicine (Baltimore). 1999;78(4):270-83.
  • Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL. ESC working group position paper on myocardial infarction with non obstructive coronary arteries. Eur Heart J. 2017;38(3):143-53.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200.
  • Wei S, Fu J, Chen L, Yu S. Performance of cardiac magnetic resonance imaging for diagnosis of myocarditis compared with endomyocardial biopsy: A meta analysis. Med Sci Monit. 2017;23:3687-96.
  • Ferreira VM, Schulz Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-76.
  • Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A. Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: Results of a validation cohort. Radiol Cardiothorac Imaging. 2019;1(3):e190010.
  • Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG. A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging. 2017; 18(10):1073-89.
  • Thomas Aretz H. Myocarditis: The Dallas criteria. Hum Pathol. 1987; 18(6):619-24.
  • Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart. 2016;102(3):184-90.
  • Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2019;74(3): 299-311.
  • Chopra H, Arangalage D, Bouleti C, Zarka S, Fayard F, Chillon S. Prognostic value of the infarct- and non infarct like patterns and cardiovascular magnetic resonance parameters on long term outcome of patients after acute myocarditis. Int J Cardiol. 2016;212:63-9.
  • Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S. A prospective study of biopsy-proven myocarditis: Prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28(11):1326-33.
  • Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B. Long term evolution and prognostic stratification of biopsy proven active myocarditis. Circulation. 2013;128(22):2384-94.
  • Ogunbayo GO, Elayi SC, Ha LD, Olorunfemi O, Elbadawi A, Saheed D. Outcomes of Heart Block in Myocarditis: A review of 31,760 patients. Hear Lung Circ. 2019;28(2):272-6.
  • Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, BÖhm M. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail. 2011;13(4):398-405.
  • Chen S, Hoss S, Zeniou V, Shauer A, Admon D, Zwas DR, et al. Electrocardiographic predictors of morbidity and mortality in patients with acute myocarditis: The importance of QRS-T angle. J Card Fail. 2018; 24(1):3-8.
  • Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O. Long term follow-up of biopsy proven viral myocarditis: Predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59(18): 1604-15.
  • Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964-76.
  • Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol. 2017;70(16):1977-87.
  • Aquaro GD, Ghebru Habtemicael Y, Camastra G, Monti L, Dellegrottaglie S, Moro C. Prognostic value of repeating cardiac magnetic resonance in patients with acute myocarditis. J Am Coll Cardiol. 2019;74(20):2439-48.
  • Karatolios K, Holzendorf V, Hatzis G, Tousoulis D, Richter A, Schieffer B. Clinical predictors of outcome in patients with inflammatory dilated cardiomyopathy. PLoS One. 2017;12(12):1-13.
  • Yang YW, Wu CH, Ko WJ, Wu VC, Chen JS, Chou NK. Prevalence of acute kidney injury and prognostic significance in patients with acute myocarditis. PLoS One. 2012;7(10):1-5.
  • Meune C, Spaulding C, Mahé I, Lebon P, Bergmann JF. Risks versus benefits of NSAIDs including aspirin in myocarditis: A review of the evi-dence from animal studies. Drug Saf. 2003;26(13):975-81.
  • Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8.
  • Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96.
  • Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. Lancet. 2019;393(10166):61-73.
  • Priori SG, Blomstrom Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea. Eur Heart J. 2015;36(41):2793-867l.
  • Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT. Predicting survival after ECMO for refractory cardiogenic shock: The survival after venoarterial ECMO (SAVE) score. Eur Heart J. 2015; 36(33):2246-56.
  • Pozzi M, Banfi C, Grinberg D, Koffel C, Bendjelid K, Robin J. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock due to myocarditis in adult patients. J Thorac Dis. 2016;8(7):E495- E502.
  • Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12(11):670-80.
  • Basso C, Calabrese F, Corrado D, Thiene G. Postmortem diagnosis in sudden cardiac death victims: Macroscopic, microscopic and molecular findings. Cardiovasc Res. 2001;50(2):290-300.
  • Anzini M, Merlo M, Artico J, Sinagra G. Arrhythmic risk prediction of acute myocarditis presenting with life-threatening ventricular tachyarrhythmias. Int J Cardiol. 2016;212:169-70.
  • Chatzidou S, Kontogiannis C, Tsilimigras DI, Georgiopoulos G, Kosmo-poulos M, Papadopoulou E. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter defibrillator. J Am Coll Cardiol. 2018;71(17):1897-906.
  • Russo A Dello, Casella M, Pieroni M, Pelargonio G, Bartoletti S, Santan-geli P. Drug- efractory ventricular tachycardias after myocarditis: Endocardial and epicardial radiofrequency catheter ablation. Circ Arrhythmia Electrophysiol. 2012;5(3):492-8.
  • Mason JW, O’Conell JB, Herskowitz A, Rose NR, McManus BM, Bi-llingham ME. clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333(5):269-75.
  • Cooper LJ, Berry, GJ MD, Shabetai, R MD. Idiopathic giantcell myocarditis natural history and treatment. N Engl J Med. 1997;336(26):1860-6.
  • Kandolin R, Lehtonen J, Salmenkivi K, Räisänen Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Hear Fail. 2013;6(1):15-22.
  • Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT. Long term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115(12):1733-8.
  • Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M. A prospective, randomized, controlled trial of Prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321(19):1061-8.
  • Wojnicz R, Nowalany Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T. Randomized, placebo controlled study for immunosuppressive treatment of inflammatory dilatad cardiomyopathy. Circulation. 2001;104:39-45.
  • Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus negative inflammatory cardiomyopathy: The TIMIC study. Eur Heart J. 2009;30(16):1995-2002.
  • Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: ASystematic review. Can J Cardiol. 2013;29(9):1034-41.
  • Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M. Interferon treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793-8.
  • McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre Amione G. Controlled trial of intravenous immune globulin in recent onset dilated cardiomyopathy. Circulation. 2001;103(18):2254-9.
  • Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5.
  • Yoshikawa T, Baba A, Akaishi M, Wakabayashi Y, Monkawa T, Kitakaze M. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column—A prospective, multicenter, randomized, within patient and parallel group comparative study to evaluate efficacy and safety. J Clin Apher. 2016;31(6):535-44.
Fonte de datos: Dialnet